Innovation

A TRANSGENIC MOUSE FOR RAPID AND SENSITIVE IN VIVO TUMOR DETECTION AND EVALUATION

University of California System: University of California, San Francisco
posted on 10/23/2009

The number of murine models for human cancer has grown rapidly in recent years and there now exist mouse models for almost all tumor types. Evaluating the effect of specific molecular alterations or therapeutic interventions in these animal models requires the ability to temporally and spatially assess the tumor burden. In many cases, however, this entails sacrificing the animal thereby limiting ability to perform follow up analysis, and necessitating the use of many more experimental animals. To address these problems, UCSF investigators have generated a general tumor reporter transgenic mouse strain designed to selectively expresses firefly luciferase in malignant tissue.

Advantages

  • Allows quantitative temporal and spatial assessment/monitoring of tumor progression.
  • Allows examination of primary tumors in an immune competent animal.
  • Allow potential detection of metastatic disease and its response to treatment.
  • Can be used to evaluate/validate anti-cancer agents in vivo.
  • Cost effective: animals do not need to be sacrificed.

Innovation Details
 

Detailed Description

The number of murine models for human cancer has grown rapidly in recent years and there now exist mouse models for almost all tumor types. Evaluating the effect of specific molecular alterations or therapeutic interventions in these animal models requires the ability to temporally and spatially assess the tumor burden. In many cases, however, this entails sacrificing the animal thereby limiting ability to perform follow up analysis, and necessitating the use of many more experimental animals.To address these problems, UCSF investigators have generated a general tumor reporter transgenic mouse strain designed to selectively expresses firefly luciferase in malignant tissue. The luciferase gene is engineered behind a region of the E2F-1 promoter, that is tumor cell specific. Detecting the resulting light emissions enables sensitive and quantitative detection of both primary and secondary tumors. These mice are designed to be crossed with tumor prone mice in order to allow an investigator to follow changes in tumor volume, for example in screening and evaluating tumor response to therapeutic interventions. This technology may accelerate and streamline the use of oncogene-driven tumor models for drug discovery and phenotyping novel target transgenics.In preliminary experiments, our investigators have successfully crossed EF2-luciferase mice to visualize tumors in a number of experimental models including spontaneous mouse metastatic prostate cancer model (TRAMP) and a chemical carcinogen derived skin tumor model.

File Number: 19085 

Disease: Cancer

Other Information:

  • Hann, B. and Balmain, A. Building validated mouse models of human cancer. Curr. Op. Cell Biol. (2001) 13(6):778.


IP Protection

Copyright: ©2009-2010, The Regents of the University of California

License Online

This innovation currently is not available for online licensing. Please contact Sunita Rajdev at University of California System: University of California, San Francisco for more information.

Request more info via email request more info
People

Case Manager:

Sunita Rajdev Sunita Rajdev

Innovations (29)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

13,272 members 17,567 innovations 176 organizations

Browse

Alfred R Berkeley, Chairman, Pipeline Financial Group, Inc., Former President and Vice Chairman, Nasdaq Stock Market, Inc.

"Our economy is inextricably intertwined with university innovations. Unfortunately, our country’s short-term outlook often interferes with the long-term possibilities of university research and collaborations with industry and entrepreneurs..."  read more...